Enosium Life Science Acquires Rweality in Strategic Transaction

Cagkan - stock.adobe.com

Enosium Life Science, a France-based company specializing in scientific services for the healthcare industry, has acquired Rweality, a consulting firm also based in France that specializes in the evaluation of public policies, technologies, and healthcare practices, in a strategic transaction that is a key step in Enosium Life Science’s growth in building a multi-specialist group across the whole value chain of health products—from clinical development to scientific communication.

The acquisition allows Enosium Life Science to consolidate its activity in the field of market access and data valorization for health products, the company stated in an April 1, 2025 company press release (1). Rweality will strengthen and complement Enosium Life Science's teams in European market access, medical communications, and the field of Health Economics and Outcomes Research (HEOR).

"I am delighted to welcome Sandrine Bourguignon, a recognized leader and expert in the public health and health economics ecosystem, and the entire Rweality team to our group. This merger fits perfectly with our development strategy and will enable us to accelerate our growth and leadership in market access consulting in France and Europe," said Antoine Amer, founder and CEO of Enosium Life Science, in the press release (1).

Rweality carries a wide range of expertise in real-world data and health technology impact assessment as well as market access and pricing strategy, development of data generation strategies, and analysis of health systems and their efficiency. Rweality personnel also have expertise in qualification of patient pathways and access to hospital markets.

"Joining Enosium Life Science is a tremendous opportunity for Rweality. Our complementary expertise and shared market vision will enable us to accelerate the demonstration of value for our clients' healthcare products," said Sandrine Bourguignon, founder and CEO of Rweality, in the press release.

This latest acquisition follows three previous acquisitions Enosium Life Science made in 2024. In October 2024, it acquired Inbeeo, a consulting firm with expertise in market access and pricing strategies for medicines and medical devices in Europe; Vyoo Agency, a company specializing in health economics and medical-economic evaluations; and the Epione Group (Epione), a France-based entity with a presence in the French medical and scientific communication market. Epione’s brands include KPL, Alinéa Plus, and Sirius Customizer (2).

The integration of Inbeeo, Vyoo Agency, and Epione allows Enosium Life Science to distinguish itself in Europe as the three acquisitions give the company the capability to offer tailor-made and innovative solutions for the pharmaceutical, biotechnology, and medtech industries. In particular, Inbeeo and Vyoo Agency support pharmaceutical and medtech companies with customized strategies and solutions that facilitate market access and the valorization of innovative medicines in an especially complex environment (e.g., pricing conditions and access and commercialization in Europe).

Meanwhile, Epione brings the expertise and medical communication know-how of its three brands, KPL (a specialist in medical affairs), Alinéa Plus (entity dedicated to scientific events and congresses), and Sirius Customizer (strategic consulting and patient journey), to meet healthcare professionals’ needs.

“I am very happy and proud to welcome Hervé Lilliu, [f]ounder of Inbeeo, Stéphane Roze, [f]ounder of Vyoo Agency, [and] Catherine Auzimour and Pierre-Louis Prost, co-founders of the Epione [G]roup as well as their 65 talents and experts recognized in France and internationally,” Amer said in the October 2024 press release announcing the three acquisitions (2). “We aim to become a European leader in the sector by pursuing our external growth strategy in the coming months, while stimulating synergies between its different entities. Our mission is to support our clients in the successful launch of their innovations in France and Europe and enable faster and wider access for European patients to quality medical innovations.”

References

1. Enosium Life Science. Enosium Life Science Consolidates Its Strategic Offering with the Acquisition of Rweality. Press Release. April 1, 2025.
2. Enosium Life Science. Enosium Life Science Takes a Major Step Towards Becoming the European Leader in Scientific Services Dedicated to the Healthcare Industry Thanks to Three Strategic Acquisitions. Press Release. Oct. 3, 2024.